Infection control in neutropenia induced by high-dose cytarabine chemotherapy

Masayuki Miyazaki, Kouji Senzaki, Hitoshi Kiyoi, Shigekatu Kohno, Yukihiro Noda, Toshitaka Nabeshima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A high-dose cytarabine (Cylocide; Ara-C: HDAC) chemotherapy has been successfully used as a postremission consolidation therapy for acute myeloid leukemia (AML). Although this chemotherapy has been estimated to cause severe myelosuppression, there has been no report about infection risk relating to HDAC chemotherapy. The purpose of this retrospective study is to evaluate the infection risk in AML patients treated with HDAC (n = 18) compared to those treated with standard-dose Ara-C (SDAC, n = 18). The mean duration of severe neutropenia (neutrophils < 500/microl) in HDAC group and SDAC was 14.8 days and 10.4 days, respectively, indicating a significant prolongation in the HDAC group (p < 0.05). The frequency of febrile neutropenia in the HDAC group tended to increase compared to that in the SDAC group (p = 0.093). The average days of usage of quinolone antimicrobial prophylaxis and aminoglycoside antibiotic injection in febrile neutropenia in the HDAC group were significantly longer than those of the SDAC group (quinolone; p < 0.01, aminoglycoside; p < 0.05). The frequency of Streptococcus infection isolated from pharyngeal mucus in the HDAC group was significantly higher than that in the SDAC group (100% versus 75%; p < 0.05). These results suggest that HDAC chemotherapy increased the infection risk compared to SDAC, and especially patients who received HDAC need a further prevention plan against gram-positive bacteria.

Original languageEnglish
Pages (from-to)2011-2015
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number12
Publication statusPublished - 01-01-2004
Externally publishedYes

Fingerprint

Cytarabine
Infection Control
Neutropenia
Drug Therapy
Febrile Neutropenia
Quinolones
Aminoglycosides
Infection
Acute Myeloid Leukemia
Antibiotic Prophylaxis
Gram-Positive Bacteria
Mucus
Streptococcus
Neutrophils
Retrospective Studies
Injections
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Miyazaki, Masayuki ; Senzaki, Kouji ; Kiyoi, Hitoshi ; Kohno, Shigekatu ; Noda, Yukihiro ; Nabeshima, Toshitaka. / Infection control in neutropenia induced by high-dose cytarabine chemotherapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 12. pp. 2011-2015.
@article{994aed218839488c96ac6554da6d8d2c,
title = "Infection control in neutropenia induced by high-dose cytarabine chemotherapy",
abstract = "A high-dose cytarabine (Cylocide; Ara-C: HDAC) chemotherapy has been successfully used as a postremission consolidation therapy for acute myeloid leukemia (AML). Although this chemotherapy has been estimated to cause severe myelosuppression, there has been no report about infection risk relating to HDAC chemotherapy. The purpose of this retrospective study is to evaluate the infection risk in AML patients treated with HDAC (n = 18) compared to those treated with standard-dose Ara-C (SDAC, n = 18). The mean duration of severe neutropenia (neutrophils < 500/microl) in HDAC group and SDAC was 14.8 days and 10.4 days, respectively, indicating a significant prolongation in the HDAC group (p < 0.05). The frequency of febrile neutropenia in the HDAC group tended to increase compared to that in the SDAC group (p = 0.093). The average days of usage of quinolone antimicrobial prophylaxis and aminoglycoside antibiotic injection in febrile neutropenia in the HDAC group were significantly longer than those of the SDAC group (quinolone; p < 0.01, aminoglycoside; p < 0.05). The frequency of Streptococcus infection isolated from pharyngeal mucus in the HDAC group was significantly higher than that in the SDAC group (100{\%} versus 75{\%}; p < 0.05). These results suggest that HDAC chemotherapy increased the infection risk compared to SDAC, and especially patients who received HDAC need a further prevention plan against gram-positive bacteria.",
author = "Masayuki Miyazaki and Kouji Senzaki and Hitoshi Kiyoi and Shigekatu Kohno and Yukihiro Noda and Toshitaka Nabeshima",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "2011--2015",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

Miyazaki, M, Senzaki, K, Kiyoi, H, Kohno, S, Noda, Y & Nabeshima, T 2004, 'Infection control in neutropenia induced by high-dose cytarabine chemotherapy', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 31, no. 12, pp. 2011-2015.

Infection control in neutropenia induced by high-dose cytarabine chemotherapy. / Miyazaki, Masayuki; Senzaki, Kouji; Kiyoi, Hitoshi; Kohno, Shigekatu; Noda, Yukihiro; Nabeshima, Toshitaka.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 12, 01.01.2004, p. 2011-2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Infection control in neutropenia induced by high-dose cytarabine chemotherapy

AU - Miyazaki, Masayuki

AU - Senzaki, Kouji

AU - Kiyoi, Hitoshi

AU - Kohno, Shigekatu

AU - Noda, Yukihiro

AU - Nabeshima, Toshitaka

PY - 2004/1/1

Y1 - 2004/1/1

N2 - A high-dose cytarabine (Cylocide; Ara-C: HDAC) chemotherapy has been successfully used as a postremission consolidation therapy for acute myeloid leukemia (AML). Although this chemotherapy has been estimated to cause severe myelosuppression, there has been no report about infection risk relating to HDAC chemotherapy. The purpose of this retrospective study is to evaluate the infection risk in AML patients treated with HDAC (n = 18) compared to those treated with standard-dose Ara-C (SDAC, n = 18). The mean duration of severe neutropenia (neutrophils < 500/microl) in HDAC group and SDAC was 14.8 days and 10.4 days, respectively, indicating a significant prolongation in the HDAC group (p < 0.05). The frequency of febrile neutropenia in the HDAC group tended to increase compared to that in the SDAC group (p = 0.093). The average days of usage of quinolone antimicrobial prophylaxis and aminoglycoside antibiotic injection in febrile neutropenia in the HDAC group were significantly longer than those of the SDAC group (quinolone; p < 0.01, aminoglycoside; p < 0.05). The frequency of Streptococcus infection isolated from pharyngeal mucus in the HDAC group was significantly higher than that in the SDAC group (100% versus 75%; p < 0.05). These results suggest that HDAC chemotherapy increased the infection risk compared to SDAC, and especially patients who received HDAC need a further prevention plan against gram-positive bacteria.

AB - A high-dose cytarabine (Cylocide; Ara-C: HDAC) chemotherapy has been successfully used as a postremission consolidation therapy for acute myeloid leukemia (AML). Although this chemotherapy has been estimated to cause severe myelosuppression, there has been no report about infection risk relating to HDAC chemotherapy. The purpose of this retrospective study is to evaluate the infection risk in AML patients treated with HDAC (n = 18) compared to those treated with standard-dose Ara-C (SDAC, n = 18). The mean duration of severe neutropenia (neutrophils < 500/microl) in HDAC group and SDAC was 14.8 days and 10.4 days, respectively, indicating a significant prolongation in the HDAC group (p < 0.05). The frequency of febrile neutropenia in the HDAC group tended to increase compared to that in the SDAC group (p = 0.093). The average days of usage of quinolone antimicrobial prophylaxis and aminoglycoside antibiotic injection in febrile neutropenia in the HDAC group were significantly longer than those of the SDAC group (quinolone; p < 0.01, aminoglycoside; p < 0.05). The frequency of Streptococcus infection isolated from pharyngeal mucus in the HDAC group was significantly higher than that in the SDAC group (100% versus 75%; p < 0.05). These results suggest that HDAC chemotherapy increased the infection risk compared to SDAC, and especially patients who received HDAC need a further prevention plan against gram-positive bacteria.

UR - http://www.scopus.com/inward/record.url?scp=16544384700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544384700&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 2011

EP - 2015

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -